|
|
1801 Watermark Drive, Suite 100
Columbus, OH 43215-1037 USA
phone:614 340 2325
fax:614 340 2320
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.ventaira.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Inhaled therapeutics solutions using generic drugs and drug delivery technologies. |
|
| Management |
| Leslie J. Williams, RN, BSN, MBA President and CEO; Janice Beauchamp, Vice President, Treasurer and Chief Financial Officer; John Denny, VP of Product Development; Bruce D. McVeety, Ph.D., Vice President, Pharmaceutical Development; David Cline, PhD, Director Labs; Bruce Davidson, MD, MPH (Clinical Director, Consultant); John Morgan, PhD (Regulatory Consultant); John Denny |
| |
|
|
| |
|
| Keywords |
| drug delivery, pharmaceuticals, inhalation, lungs, pulmonary, generics, DrugDelivery |
|
|
|
| Description |
|
Ventaira develops inhaled therapeutics solutions using generic drugs in combination with its Mystic inhaled drug delivery technology. |
|
| Technology / Differentiation |
| Ventaira inhalation devices utilizing Mystic technology (EHD), deliver a low velocity, soft (isokinetic) cloud of uniformly sized particles with over 80 percent of the drug getting to the lungs. This is accomplished without the need for liquid propellants or other pressurized systems. The aerosol mist is delivered using the patient's own breath (inspiration), meaning that the patient can easily control the drug delivery. |
|
|
| Funding |
| Ventaira Pharmaceutical's was incubated at Battelle from 1997 to 2000. Initial funding was then provided by Battelle in April, 2000, as the company established itself as a free-standing business. Ventaira raised its first institutional round of $25 million in March, 2003. In March, 2005 a Series C round of $13.5 million was completed. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members